Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY

Dr. Reddy's Laboratories — Q4 FY25 Earnings Presentation

17 slides from Dr. Reddy's Laboratories's earnings presentation, May 9, 2025

  1. Slide 1: Regulation 30 intimation: Q4 FY25 results presentation

    Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com May 9, 2025 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE L

  2. Slide 2: Q4 & FY25 Financial Results

    Q4 & FY25 FINANCIAL RESULTS May 9, 2025 1

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and

  4. Slide 4: Q4 Performance FY25

    Record annual revenue & highest ever EBITDA in FY25 Q4 FY25 Performance Performance ₹ 8,506Cr ₹ 32,554 Cr FINANCIAL HIGHLIGHTS Revenues Revenues 20%YoY 2% QoQ 17%YoY  Highest ever quarterly revenues & profits in Q4 ₹ 2,475 Cr | 29% ₹ 9,213 Cr | 28%  Double-digit FY25 Revenue growth at 17% EBITDA |

  5. Slide 5: Continued progress on our priorities, in line with stated strategy

    Continued progress on our priorities, in line with stated strategy KEY HIGHLIGHTS  UK integration completed in May’25 for acquired Nicotine Replacement Therapy (NRT)  Partnered with Henlius for exclusive commercialization rights of daratumumab biosimilar for the US & Europe  Partnered with Bio-Th

  6. Slide 6: Recognitions for our continued efforts in sustainability

    Recognitions for our continued efforts in sustainability KEY HIGHLIGHTS  EcoVadis score @73, among top 15% assessed globally  ‘CSR Program of the Year’ at Financial Express – Pharma Awards 2025  CII’s ‘Climate Action Program 2.0° Award’ in ‘Resilient’ category - Light Manufacturing Sector  ‘Lead

  7. Slide 7: Q4: Overall double-digit growth driven by performance across geographies

    Q4 : Overall double-digit growth driven by performance across geographies, aided by Consumer healthcare (NRT) revenues Q4 REVENUE BY SEGMENT GLOBAL GENERICS SPLIT IN Q4 ₹ 3,559 Cr ₹ 1,275* Cr North America Europe GLOBAL GENERICS 145%YoY* 5% QoQ* 9%YoY 5% QoQ 89% 42% 15% ₹ 8,506 Cr 20%YoY# 2%QoQ# PSA

  8. Slide 8: FY25: Double-digit growth across geographies

    FY25 : Double-digit growth across geographies FY25 REVENUE BY SEGMENT GLOBAL GENERICS SPLIT IN FY25 ₹ 14,516 Cr ₹ 3,588* Cr North America Europe GLOBAL GENERICS 12%YoY 75%YoY* 89% 45% 11% ₹ 32,554 Cr 17%YoY# PSAI 10% 17% OTHERS ₹ 5,373 Cr 1% India 16%YoY ₹ 28,955 Cr ₹ 3,385 Cr Pharmaceutical Service

  9. Slide 9: Investing and upscaling commercial and R&D capabilities

    Investing Q1 FY24 and upscaling commercial and R&D capabilities Performance GROSS MARGINS (% of Revenues) SG&A EXPENSES (% of Revenues) R&D EXPENSES (% of Revenues) Q4FY25 55.6% Q4FY25 28.3% Q4FY25 8.5% Q3FY25 58.7% Q3FY25 28.9% Q3FY25 8.0% Q4FY24 58.6% Q4FY24 28.9% Q4FY24 9.7% CAPEX (₹ Cr) FREE CAS

  10. Slide 10: North America Q4FY25 Performance

    Demand-led growth offset by price erosion North America Q4FY25 Performance MARKET NEW PENDING 42% PERFORMANCE LAUNCHES APPROVAL 3.9% vs. 3.8% 7 18 73 3 DRL Growth vs. US Generic Q4 FY25 ANDAs NDAs Market Growth* Includes 46 Para IVs & 20 FTFs *As per IQVIA MAT for Feb’ 25 Revenues ₹ 3,559 Cr 9%YoY 5

  11. Slide 11: India Q4FY25 Performance

    Growing in double digits, new products performance has been encouraging India Q4FY25 Performance MARKET NEW BRAND BRANDS IN 15% PERFORMANCE LAUNCHES TOP 300 IPM 8.4% vs. 8.0% 23 17 + Sanofi, Nestlé DRL Growth vs. IPM Growth* FY25 *As per IQVIA MAT Mar’25 As per IQVIA Mar’25 Revenues ₹ 1,305 Cr 16%Yo

  12. Slide 12: Emerging Markets Q4FY25 Performance

    Emerging New launches & higher sales volumes drive double-digit growth Markets Q4FY25 Performance REVENUE SPLIT 16% ₹ 655 Cr Russia 31%YoY 7% QoQ  YoY growth from new product launches & higher volumes  QoQ decline due to slower volume growth CISR Revenues 17% ₹ 244 Cr NEW ₹ 1,398 Cr RoW CISR 36% 1

  13. Slide 13: Europe Q4FY25 Performance

    Base business growth aided by acquired NRT business revenues Europe Q4FY25 REVENUE SPLIT Performance ₹ 597 Cr STRATEGIC 15% Acquired NRT Business HIGHLIGHTS 1% QoQ  Integration of 1st country, UK, completed  Next wave of countries to be ₹ 355 Cr integrated - Nordics Germany France, Italy, Acquired

  14. Slide 14: PSAI Q4FY25 Performance

    PSAI Growth led by new launches and higher API volumes as well Q4FY25 as growth in services business Performance 11% GROSS NEW Revenues MARGIN FILINGS (DMFs) ₹ 956 Cr 26.3% 27.1% 52 111 16%YoY 16% QoQ Q4 FY25 Q4 FY25 GROWTH DRIVERS  API growth driven by new launches & higher volumes.  Growth in CD

  15. Slide 15: In Summary

    In Summary A diversified business model with broad based levers STRENGTHEN CORE BUSINESSES ACROSS MARKETS WITH A ROBUST PRODUCT PORTFOLIO INVEST IN INNOVATIVE & DIFFRENTIATED PRODUCTS (NCEs, CDMO, CONSUMER HEALTH) DRIVE OPERATIONAL EFFICIENCY & PRODUCTIVITY FOCUS ON QUALITY AND COMPLIANCE STRENGTHEN

  16. Slide 16: About key metrics and non-GAAP Financial Measures

    About key metrics and non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are a

  17. Slide 17: Good Health Can't Wait.

    Good Health Can’t Wait. 16 | May 9, 2025 | Q4 & FY25 Results Update | As per consolidated financial statements under IFRS

Dr. Reddy's Laboratories — Q4 FY25 Earnings Presentation on 6ix